Allopax
Product Images NDC 69817-0201

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Allopax (NDC 69817-0201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pharmagenetico Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Allopax Labels (Allopax Label 101915)

Allopax Labels (Allopax Label 101915)
Front Carton Label: The NDC (National Drug Code) number for the AlleePAX medication is 69817-0201-1. It is intended for prescription use only and should be stored at room temperature, protected from light and out of reach of children. The LOT number is 12345678, and the container should be tightly closed. It is for external use only, and contact with eyes should be avoided. It should be prepared as instructed before dispensing. Marketed by PharmaGenetico LLC, AlleePAX is a pharmacy drug in San Antonio, TX 78257. Back Carton Label: The back carton label declares the same NDC number and is intended for prescription use only. The FDA (Food and Drug Administration) has not approved Allo*PAX to cure, treat, or mitigate disease. Allo*PAX is intended for preparation following state and federal regulations and is available only by prescription. Each pack contains Levocetirizine Dihydrochloride and Loratadine USP, and it is only available for use upon prescription. It is labeled Rx Only and has a weight of 60g when dispensed.*
FDA Label Image

Allopax Insert (Allopaxinsert)

Allopax Insert (Allopaxinsert)
The AlloePAX pack contains pre-weighed Levocetirizine dihydrochloride, Loratadine, and PCCA Lipoderm® base cream. The pharmacist must empty the PCCA Lipoderm® base into an appropriate mixing container and then combine the Loratadine powder with the PCCA Lipoderm® base. The mixture should be stirred gently for about 1-2 minutes until it appears homogeneous. Next, the Levocetirizine dihydrochloride powder should be combined with the PCCA Lipoderm® base/Loratadine mixture and stirred gently for about 1-2 minutes until it appears homogeneous. The formulation should be stored at controlled room temperature and discarded after 30 days of being dispensed. The product should only be used externally and kept out of reach of children. The pharmacy is responsible for properly labeling the finished product according to state and federal guidelines. The active ingredients include Levocetirizine dihydrochloride and Loratadine with the inactive ingredient being PCCA Lipoderm®.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.